The warning comes from thyroid C-cell tumors in rats and mice; whether the drugs cause MTC in people has not been determined.2
What MTC is
MedlinePlus describes two forms. Sporadic MTC does not run in families; most cases are sporadic, and this form mainly affects older adults. Hereditary MTC runs in families, and the risk is higher with a family history of MTC or of multiple endocrine neoplasia, MEN.1 It often begins as a small lump, or nodule, in the thyroid, sometimes with swollen lymph nodes in the neck. Symptoms can include swelling of the neck, hoarseness, breathing problems, cough, coughing up blood, and diarrhea caused by high calcitonin. Treatment is surgery to remove the thyroid and nearby lymph nodes. MedlinePlus puts 10-year survival at 65%.1
What the warning says
- The finding. In rodents, semaglutide caused thyroid C-cell tumors that rose with dose and with length of treatment, at exposures relevant to treatment in people.
- The unknown. It is unknown whether Wegovy causes C-cell tumors, including MTC, in humans, because the relevance of the rodent tumors to people has not been determined.
- Who must not take it. People with a personal or family history of MTC, and people with MEN 2, multiple endocrine neoplasia syndrome type 2.
- Symptoms to report. A mass in the neck, trouble swallowing, shortness of breath, or hoarseness that does not go away.
Wegovy label, boxed warning.2
The Saxenda label for liraglutide carries the same warning.3 The Foundayo label for orforglipron, a small molecule, adds a twist: orforglipron is not active at the GLP-1 receptor of rats or mice and did not produce tumors in them. The label keeps the warning anyway, because the drug does act on the human receptor and the tumors seen with other drugs of the class are considered effects of that receptor.4
Why routine tests are not advised
The Wegovy label says routine monitoring of calcitonin or thyroid ultrasound is of uncertain value for finding MTC early in people on the drug. Such monitoring may lead to unnecessary procedures, because the calcitonin test is not specific and thyroid disease is common in the population. People with MTC usually have calcitonin above 50 ng/L, and a high result, or a nodule found on exam or imaging, should be evaluated further.2
What human studies show
Two large studies of people with type 2 diabetes reached different answers. They are reported as hazard ratios, where 1.0 means no difference from the comparison drug.
- Scandinavia, 2024. A cohort from Denmark, Norway and Sweden compared 145,410 GLP-1 users with 291,667 users of DPP-4 inhibitors over a mean of 3.9 years. Thyroid cancer occurred at 1.33 and 1.46 cases per 10,000 person-years, a hazard ratio of 0.93, from 0.66 to 1.31. For MTC the hazard ratio was 1.19, with a range from 0.37 to 3.86.5
- France, 2023. A case-control study in the national health insurance database matched 2,562 people with thyroid cancer to 45,184 without it. Use of a GLP-1 medicine for 1 to 3 years was linked with more thyroid cancer, a hazard ratio of 1.58, and more MTC, 1.78, with a range from 1.04 to 3.05.6
The Scandinavian authors concluded that GLP-1 use was not associated with a substantially increased risk over the mean follow-up. Neither study changes the label: the warning and the contraindications stand.
Sources
- MedlinePlus. Thyroid cancer - medullary carcinoma. A.D.A.M. Medical Encyclopedia; review date January 29, 2026, read November 20, 2026. medlineplus.gov
- WEGOVY (semaglutide) injection prescribing information. Novo Nordisk; DailyMed, version 19, published June 30, 2026; boxed warning and section 5.1. dailymed.nlm.nih.gov
- SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version 22, published June 15, 2026; boxed warning. dailymed.nlm.nih.gov
- FOUNDAYO (orforglipron) tablets prescribing information. Eli Lilly; DailyMed, version 10, published August 13, 2026; boxed warning. dailymed.nlm.nih.gov
- Pasternak B, Wintzell V, Hviid A, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ 2024;385:e078225. doi:10.1136/bmj-2023-078225
- Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023;46:384-390. doi:10.2337/dc22-1148
Related analyses
Ozempic side effects: how common each one is by dose, and when they ease
Mounjaro side effects: how common each one is by dose, and when they ease
Wegovy side effects: how common each one is, when it peaks and how long it lasts
Zepbound side effects timeline: when they start, how long they last, when they ease
Log any neck lump, hoarseness or trouble swallowing with the date, and show your doctor.
Open Dose Insider